Scientists discover new compound which could improve photodynamic therapy for cancer

Pinterest LinkedIn Tumblr +

PDT does not always kill cells deep within a cancerous tumour, allowing tumours to grow back again.

The new compound uses penetrating infrared light to damage cells directly and potentially improve the success rate of PDT

Researchers at the University of Sheffield in the UK have synthesised a new compound which could improve the success rate of photodynamic therapy when treating cancer.

The key to photodynamic therapy (PDT) is a compound known as a sensitiser, a light-sensitive medicine given to the patient, which when activated by light produces highly reactive oxygen-based species which kill the cancer cells.

However, current PDT treatment has two main drawbacks when it comes to killing tumours.

First, currently used sensitisers are only activated by light energies that do not penetrate tissues, like skin, very deeply.

Second, many tumours have low amounts of oxygen, so photoactivated sensitisers cannot generate the toxic compounds which kill cancer cells.

Now scientists at the University of Sheffield have developed a new compound which solves both of these problems in one go.

Not only is the new compound activated by infrared or red light which can penetrate deep into the tumour, but it also directly damages DNA within cells without having to rely on oxygen.

Researchers at the University of Sheffield have tested the compound in skin cancer tumour models and observed that it killed cancer cells deep into these model tumours.

The next step in the research will look at skin models, testing whether the compound can kill the tumour but leave healthy skin undamaged.

Professor Jim Thomas, from the University of Sheffield’s Department of Chemistry, who led the study said: “PDT is potentially a very attractive way to treat diseases such as skin cancer as it only works when the laser light is applied, so the effect can be focused into a specific place on or in the body.

“The sensitiser we have developed can potentially solve the two main problems that prevent PDT from being a commonly used anticancer treatment.”

The research, published in the Journal of the American Chemical Society, was carried out by scientists from the University of Sheffield’s Departments of Chemistry and Materials Science and Engineering and the Science and Technology Facilities Council (STFC) Central Laser Facility.

Source: University of Sheffield


About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.